



## Cancer Prevention and Control CIRB Meeting Agenda

April 28, 2022

---

---

### I. Amendment Prior to Activation

**MDA21-06-01**, A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome (Protocol Version Date 03/09/22)

---

---

### II. Continuing Review

**A221505**, RT Charm: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (Protocol Version Date 10/22/21)

---

---

### III. Continuing Review

**A222004**, A Randomized Phase III Trial Of Olanzapine Versus Megestrol Acetate For Cancer-Associated Anorexia (Protocol Version Date 01/20/22)

---

---

### IV. Continuing Review

**EA1151**, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Protocol Version Date 02/09/22)

---

---

### V. Continuing Review

**EA2185**, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs (Protocol Version Date 08/18/21)

---

---

### VI. Continuing Review

**NWU20-01-03**, Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): RELIEF-NAFLD (Protocol Version Date 12/02/21)

---

---

**VII. Continuing Review**

**URCC-16070**, Treatment of Refractory Nausea (Protocol Version Date 07/17/20)

---

---

**VIII. New Study ReReview**

**S2108CD**, A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy (Protocol Version Date 04/18/22)

---

---

**IX. New Study ReReview**

**UWI20-04-01**, A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer (Protocol Version Date 04/12/22)

---

---

**X. New Study - Initial Review**

**A222101**, An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy (Protocol Version Date 02/02/22)

---

---

**XI. Amendment**

**S1614**, A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors (Protocol Version Date 02/22/22)

---

---